Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1) an open-label, randomised, multicentre关于患者的疗效.pdf

Articles Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Paul Y Kwo, Eric J Lawitz, Jonathan McCone, Eugene R Schiff , John M Vierling, David Pound, Mitchell N Davis, Joseph S Galati, Stuart C Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank H Anderson, Ira M Jacobson, Raymond Rubin, Kenneth Koury, Lisa D Pedicone, Cliff ord A Brass, Eirum Chaudhri, Janice K Albrecht, on behalf of the SPRINT-1 investigators* Summary Background Peginterferon plus ribavirin achieves sustained virological response (SVR) in fewer than half of patients Lancet 2010; 376: 705–16 with genotype 1 chronic hepatitis C virus infection treated for 48 weeks. We tested the effi cacy of boceprevir, an NS3 This online publication has hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin. been corrected. The corrected version fi rst appeared at TheL on Methods In part 1 of this trial, undertaken in 67 sites in the USA, Canada, and Europe, 520 treatment-naive patients October 8, 2010 with genotype 1 hepatitis C virus infection were randomly assigned to receive peginterferon alfa-2b 1·5 μg/kg plus